ClinicalTrials.gg
Active, not recruitingNCT05852938Updated Apr 1, 2026

A Study of Zigakibart in Adults With IgA Nephropathy

A Phase 3 interventional study of BION-1301 and Placebo in IgA Nephropathy and Immunoglobulin A Nephropathy, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 200 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
383
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Glomerulonephritis, IGA by Novartis — 9 open to participants now, 12 under way, 7 of them phase 3. Glomerulonephritis, IGA · Novartis.

Enrollment
4th of 14
383 · median 108
Started
2023
with 1 other
Phase 3
8 of 18
5 open now
Primary completion
2027-08
later than 2 of 11 live
Registered
8th of 18
by date

Among the 18 studies in Glomerulonephritis, IGA by Novartis, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 in phase 3, reaches primary completion later than 2 of the 11 other live ones, and was the 8th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

9 of the 18 studies in Glomerulonephritis, IGA by Novartis are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 69 Glomerulonephritis, IGA studies recruiting now, 40 (58%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Glomerulonephritis, IGA by Novartis, or all of them as a file.
02

Study summary

Safety and Efficacy of BION-1301 in Adults with IgA Nephropathy

Read the detailed description

Approximately 330 participants with eGFR ≥ 30 mL/min/1.73m\^2 and with biopsy-proven IgAN will be randomized to receive 600 mg Q2W BION-1301, Novartis FUB523, or a matched placebo for 104 weeks. An additional exploratory cohort, not included in the primary analysis, will be comprised of approximately 20 participants (10 participants per arm) with biopsy-confirmed IgAN and eGFR of ≥ 20 to \< 30 mL/min/1.73 m\^2. The exploratory cohort will be randomized using the same schema as the primary cohort.

The primary objective of the study is to evaluate the effect of BION-1301 versus placebo on eGFR as measured by the change from Baseline in eGFR.

Following completion of the 104-week treatment period, subjects may be eligible to enroll in an open-label extension (OLE) study to receive open-label treatment with BION-1301 under a separate protocol. Subjects who do not enroll in the OLE will enter the protocol-specified 24-week safety follow-up period.

To facilitate study participation over this time period, other visits may be remote (away from study site) for participants who elect to self-administer the study drug.

03

Conditions studied

  • IgA Nephropathy
  • Immunoglobulin A Nephropathy

Keywords

  • Kidney Diseases
  • Kidney Diseases, Chronic
  • Urological Diseases
  • Glomerulonephritis
  • Glomerular Disease
  • Glomerulonephritis, IGA
  • Glomerulopathy
  • Immunoglobulin Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged ≥ 18 years at the time of signing the form (ICF) prior to initiation of any study specific activities/procedures.
  • -proven IgAN diagnosed within the past 10 years prior to Screening, that, in the opinion of the Investigator, is not due to secondary causes. A pseudonymized copy of the report must be available for review by the Sponsor or designee prior to randomization. If biopsy report within 10 years is not available, re-biopsy may be permitted upon discussion with the Sponsor.
  • ≥ 30 mL/min/1.73m\^2 at Screening based on the 2021 CKD-EPI equation.
  • Total urine protein ≥ 1.0 g/day or UPCR ≥ 0.7 g/g (700 mg/g), as measured from an adequate 24-hour urine collection at Screening by a central laboratory.
  • Stable on a maximally tolerated dose of angiotensin-converting enzyme inhibitors (ACEi) and/or angiotensin II receptor blockers (ARB) for at least 12 weeks prior to Screening unless intolerant to ACEi and ARB. May also be on a stable and well tolerated dose of sodium glucose cotransporter-2 inhibitors (SGLT2i), endothelin receptor antagonists (ERAs) and/or mineralocorticoid receptor antagonists (MRAs) for at least 12 weeks prior to Screening for the treatment of IgAN. Subjects are expected to stay on a stable dose of ACEi, ARB, SGLT2i, ERAs, and/or MRAs for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Secondary forms of IgAN as determined by the Investigator, in the setting of systemic disorders, infections, disorders or neoplasias.
  • Diagnosis of IgA Vasculitis.
  • Current or history of nephrotic syndrome.
  • Received systemic therapy including budesonide (Tarpeyo/Kinpeygo) for > 14 days within 12 weeks prior to Screening.
  • Use of systemic medications.
  • IgG levels \< 6 g/L at Screening.

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
383 participants (actual)

Study arms

  • Experimental
    BION-1301

    600mg subcutaneous administration every 2 weeks for 104 weeks

    Drug: BION-1301

  • Placebo comparator
    Placebo

    subcutaneous administration every 2 weeks for 104 weeks

    Drug: Placebo

Interventions

  • BION-1301 Pre-Filled Syringe (PFS) 600mg subcutaneous administration every 2 weeks for 104 weeks.

    Also known as: Zigakibart, FUB523

  • DrugPlacebo

    Placebo - PFS subcutaneous administration every 2 weeks for 104 weeks.

06

What researchers measure

Primary outcomes

  1. Change from baseline in eGFR

    Change from Baseline to Week 104 in eGFR using the CKD-EPI 2021 creatinine equation

    Time frame: Baseline and 104 weeks or approximately 2 years

Secondary outcomes

  1. Change in proteinuria (natural log UPCR)

    Change in urine protein: creatinine ratio (UPCR) from baseline to week 40

    Time frame: Baseline and 40 weeks or approximately 9 months

  2. Annualized rate of change in eGFR

    Annualized eGFR slope estimated over 104 weeks using the CKD-EPI 2021 creatinine equation

    Time frame: 104 weeks or approximately 2 years

  3. Effect of BION-1301 on specific clinical composite endpoints (30% eGFR reduction)

    Percent of participants meeting the composite endpoint of experiencing at least 1 of the following during the study: * At least 30% reduction in eGFR sustained for at least 30 days * eGFR \< 15 mL/min/1.73m\^2, sustained for at least 30 days * Chronic dialysis, ≥ 30 days * Kidney transplantation * All-cause mortality

    Time frame: Baseline and Weeks 4, 12, 24, 40, 52, 64, 76, 88, and 104

  4. Effect of BION-1301 on specific clinical composite endpoints (40% eGFR reduction)

    Percent of participants meeting the composite endpoint of experiencing at least 1 of the following during the study: * At least 40% reduction in eGFR sustained for at least 30 days * eGFR \< 15 mL/min/1.73m\^2, sustained for at least 30 days * Chronic dialysis, ≥ 30 days * Kidney transplantation * All-cause mortality

    Time frame: Baseline and Weeks 4, 12, 24, 40, 52, 64, 76, 88, and 104

  5. Percent Change in Proteinuria and Total Urine Protein

    Percent of participants achieving reduction of proteinuria to \< 1.0 g/day at Week 40 and a ≥ 25% decrease in total urine protein from Baseline

    Time frame: 40 weeks or approximately 9 months

07

Study locations

200 sites
  • University of Alabama at Birmingham: The Kirklin Clinic
    Birmingham, Alabama 35233-1926, United States
  • Nephrology Consultants, LLC
    Huntsville, Alabama 35805-4104, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Valiance Clinical Research
    South Gate, California 90280-5219, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Denver Nephrology Research Division
    Denver, Colorado 80230-6441, United States
  • Vida Medical Centers - Pembroke Pines
    Pembroke Pines, Florida 33023-2213, United States
  • NorthShore University HealthSystem
    Evanston, Illinois 60201-1700, United States
  • Nephrology Associales of Northern Illinois and Indiana
    Hinsdale, Illinois 60521-3640, United States
  • Nephrology Associates of Northern Illinois and Indiana - 7836 W Jefferson Blvd
    Fort Wayne, Indiana 46804, United States
  • University Of Iowa Hospitals And Clinics
    Iowa City, Iowa 52242-1009, United States
  • Intermed Consultants
    Edina, Minnesota 55435-2129, United States
  • Capital District Renal Physicians
    Clifton Park, New York 12065, United States
  • Nephrology Associates PC - Flushing
    Flushing, New York 11355-5045, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029-6504, United States
  • University of Cincinnati College of Medicine - 231 Albert Sabin Way
    Cincinnati, Ohio 45267-2827, United States
  • Cleveland Clinic-9500 Euclid Ave
    Cleveland, Ohio 44109-1900, United States
  • OHSU - Oregon Clinical and Translational Research Institute
    Portland, Oregon 97239, United States
  • Northeast Clinical Research Center, LLC
    Bethlehem, Pennsylvania 18017-2159, United States
  • Columbia Nephrology Associates , P.A. - Columbia
    Columbia, South Carolina 29203-6476, United States
  • Knoxville Kidney Center, PLLC - Frenova F1
    Knoxville, Tennessee 37923, United States
  • Dallas Renal Group - 1411 N Beckley Ave
    Dallas, Texas 75230, United States
  • Dallas Renal Group - Waxachie - 2460 N. I-35
    Dallas, Texas 75237-3461, United States
  • DaVita Clinical Research
    El Paso, Texas 79925, United States
  • University of Texas MD Anderson Cancer Center-1155 Pressler
    Houston, Texas 77030-2348, United States
  • East Texas Nephrology Associates
    Lufkin, Texas 75904-3132, United States
  • Nephrology Associates of Northern Virginia-8501 Arlington Blvd
    Fairfax, Virginia 22033-1907, United States
  • Swedish Center for Comprehensive Care
    Seattle, Washington 98104, United States
  • Novartis Investigative Site
    La Plata, Buenos Aires B1902COS, Argentina
  • Novartis Investigative Site
    Catamarca, Catamarca Province K4700, Argentina
  • Novartis Investigative Site
    Barracas, Ciudad Autónoma de BuenosAires C1280AEB, Argentina
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2013DTC, Argentina
  • Novartis Investigative Site
    Santa Fe, Santa Fe Province S3000EPV, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1425, Argentina
  • Novartis Investigative Site
    Gosford, New South Wales 2250, Australia
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Novartis Investigative Site
    Liverpool, New South Wales 2170, Australia
  • Novartis Investigative Site
    Penrith, New South Wales 2750, Australia
  • Novartis Investigative Site
    St Leonards, New South Wales 2065, Australia
  • Novartis Investigative Site
    Cairns North, Queensland 4870, Australia
  • Novartis Investigative Site
    Box Hill, Victoria 3128, Australia
  • Novartis Investigative Site
    St Albans, Victoria 3021, Australia
  • Novartis Investigative Site
    Bonheiden, Antwerpen 2820, Belgium
  • Novartis Investigative Site
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Novartis Investigative Site
    Roeselare, West-Vlaanderen 8800, Belgium
  • Novartis Investigative Site
    Liège, Liège, Belgium
  • Novartis Investigative Site
    Lodelinsart, 6042, Belgium
  • Novartis Investigative Site
    Woluwe-Saint-Lambert, 1200, Belgium
  • Novartis Investigative Site
    Santana, Amapá 68925-000, Brazil
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Novartis Investigative Site
    Maringá, Paraná 87013-040, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90035-074, Brazil
  • Novartis Investigative Site
    Joinville, Santa Catarina 89227-680, Brazil
  • Novartis Investigative Site
    São Bernardo do Campo, São Paulo 09780-000, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 01323-001, Brazil
  • Novartis Investigative Site
    São Paulo, 04023-900, Brazil
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Brampton, Ontario L6Z 4N5, Canada
  • Novartis Investigative Site
    East York, Ontario M4C 5T2, Canada
  • Novartis Investigative Site
    London, Ontario N6A 5A5, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2N2, Canada
  • Novartis Investigative Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Hefei, Anhui 230601, China
  • Novartis Investigative Site
    Beijing, Beijing Municipality 100034, China
  • Novartis Investigative Site
    Foshan, Guangdong 528000, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510080, China
  • Novartis Investigative Site
    Guangzhou, Guangdong 510280, China
  • Novartis Investigative Site
    Shenzhen, Guangdong 518036, China
  • Novartis Investigative Site
    Nanning, Guangxi 530021, China
  • Novartis Investigative Site
    Guiyang, Guizhou 550002, China
  • Novartis Investigative Site
    Wuhan, Hubei 430060, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 210029, China
  • Novartis Investigative Site
    Nantong, Jiangsu 226001, China
  • Novartis Investigative Site
    Wuxi, Jiangsu 214023, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Jinan, Shandong 250021, China
  • Novartis Investigative Site
    Qingdao, Shandong 266005, China
  • Novartis Investigative Site
    Shanghai, Shanghai Municipality 200040, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 030001, China
  • Novartis Investigative Site
    Taiyuan, Shanxi 650000, China
  • Novartis Investigative Site
    Chengdu, Sichuan 610072, China
  • Novartis Investigative Site
    Ürümqi, Xinjiang 830001, China
  • Novartis Investigative Site
    Wulumuji, Xinjiang 830054, China
  • Novartis Investigative Site
    Hangzhou, Zhejiang 310009, China
  • Novartis Investigative Site
    Taizhou, Zhejiang 317000, China
  • Novartis Investigative Site
    Zagreb, City of Zagreb 10000, Croatia
  • Novartis Investigative Site
    Biškupec Zelinski, 10380, Croatia
  • Novartis Investigative Site
    Rijeka, 51000, Croatia
  • Novartis Investigative Site
    Vinkovci, 32100, Croatia
  • Novartis Investigative Site
    Prague, Praha, Hlavní Mesto 128 08, Czechia
  • Novartis Investigative Site
    Nîmes, Gard 30029, France
  • Novartis Investigative Site
    Lille, Nord 59000, France
  • Novartis Investigative Site
    Lyon, Rhône 69437, France
  • Novartis Investigative Site
    Grenoble, 38043, France
  • Novartis Investigative Site
    Paris, 75010, France
  • Novartis Investigative Site
    Paris, 75015, France
  • Novartis Investigative Site
    Augsburg, Bavaria 86156, Germany
  • Novartis Investigative Site
    Hanover, Lower Saxony 30459, Germany
  • Novartis Investigative Site
    Hanover, Lower Saxony 30625, Germany

Showing the first 100 of 200 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Dulos J, Kreijtz J, Vink P, Cotton V, Kuo JJ, Lo J, Jansen W, Bakker J, Driessen L, Guadagnoli M, van Zandvoort P, Warncke M, Medema JP, Barratt J, van Eenennaam H, Van Elsas A. Zigakibart Potently Inhibits A Proliferation-Inducing Ligand-Mediated IgA Production, Addressing IgAN Pathogenesis Root Causes. Kidney Int Rep. 2026 Apr 6;11(6):106516. doi: 10.1016/j.ekir.2026.106516. eCollection 2026 Jun. PubMed 42205925 ↗
  • Kooienga L, Lo J, Lee EY, Kim SG, Thomas H, Workeneh B, Agha I, Song Y, Smith W, van Eenennaam H, Van Elsas A, Dulos J, Barratt J. Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy. Kidney Int. 2025 Sep;108(3):445-454. doi: 10.1016/j.kint.2025.05.006. Epub 2025 Jun 5. PubMed 40482854 ↗
  • Ahmad SB, Jefferson JA. Targeting B Cells and Plasma Cells in Glomerular Disease. J Am Soc Nephrol. 2025 Jun 4;36(9):1844-1857. doi: 10.1681/ASN.0000000772. PubMed 40465397 ↗
  • Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3. PubMed 38299639 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Aug 2027, 49 months after the start.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's planned 49 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2023
First posted
May 10, 2023
StartActual
Jul 6, 2023
Primary completionEst.
Aug 10, 2027
CompletionEst.
Jan 25, 2028
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05852938
Responsible party
Sponsor
First posted
May 10, 2023
Start date
Jul 6, 2023
Primary completion
Aug 10, 2027 (estimated)
Completion
Jan 25, 2028 (estimated)
Last update
Apr 1, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zigakibart

Start the discussion